Gliomatosis cerebri

20 Years of experience at the Children's Hospital of Philadelphia

Gregory Armstrong, Peter C. Phillips, Lucy B. Rorke-Adams, Alexander R. Judkins, A. Russell Localio, Michael J. Fisher

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

BACKGROUND. Gliomatosis cerebri (GC) is a rare and typically fatal glial neoplasm of the central nervous system. In this report, the authors describe the largest cohort of children to date with GC and explore relations between potential prognostic factors, treatment, and survival. METHODS. Imaging, pathologic, and outcome data were reviewed from 13 patients who were diagnosed with GC and were treated at the Children's Hospital of Philadelphia (CHOP) between 1982 and 2005. All patients had GC confirmed by biopsy. Twelve patients received cranial irradiation, and 8 of those patients received adjuvant chemotherapy. A single patient age 1 year received chemotherapy alone. A review of the literature identified 51 pediatric patients with GC. RESULTS. The progression-free survival rate in this study was 13% (range, 1.5-43 months), and the overall survival (OS) rate was 64% (range, 6.5-67 months) at 2 years. OS was significantly shorter for patients who presented in the first decade of life (P = .04). The time to progression was prolonged significantly for patients who had no evidence of tumor enhancement on imaging studies (P = .03). When survival data from patients reported in the literature were combined with the CHOP cohort, treatment prolonged OS significantly (P = .003). CONCLUSIONS. The outcome of pediatric patients with GC was extremely poor; however, the current results indicated that treatment may prolong OS. Age < 10 years and contrast enhancement on magnetic resonance imaging studies at diagnosis may be risk factors for shorter survival in pediatric patients with GC.

Original languageEnglish (US)
Pages (from-to)1597-1606
Number of pages10
JournalCancer
Volume107
Issue number7
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Neuroepithelial Neoplasms
Survival
Pediatrics
Survival Rate
Cranial Irradiation
Central Nervous System Neoplasms
Adjuvant Chemotherapy
Neuroglia
Disease-Free Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Armstrong, G., Phillips, P. C., Rorke-Adams, L. B., Judkins, A. R., Localio, A. R., & Fisher, M. J. (2006). Gliomatosis cerebri: 20 Years of experience at the Children's Hospital of Philadelphia. Cancer, 107(7), 1597-1606. https://doi.org/10.1002/cncr.22210

Gliomatosis cerebri : 20 Years of experience at the Children's Hospital of Philadelphia. / Armstrong, Gregory; Phillips, Peter C.; Rorke-Adams, Lucy B.; Judkins, Alexander R.; Localio, A. Russell; Fisher, Michael J.

In: Cancer, Vol. 107, No. 7, 01.10.2006, p. 1597-1606.

Research output: Contribution to journalArticle

Armstrong, G, Phillips, PC, Rorke-Adams, LB, Judkins, AR, Localio, AR & Fisher, MJ 2006, 'Gliomatosis cerebri: 20 Years of experience at the Children's Hospital of Philadelphia', Cancer, vol. 107, no. 7, pp. 1597-1606. https://doi.org/10.1002/cncr.22210
Armstrong G, Phillips PC, Rorke-Adams LB, Judkins AR, Localio AR, Fisher MJ. Gliomatosis cerebri: 20 Years of experience at the Children's Hospital of Philadelphia. Cancer. 2006 Oct 1;107(7):1597-1606. https://doi.org/10.1002/cncr.22210
Armstrong, Gregory ; Phillips, Peter C. ; Rorke-Adams, Lucy B. ; Judkins, Alexander R. ; Localio, A. Russell ; Fisher, Michael J. / Gliomatosis cerebri : 20 Years of experience at the Children's Hospital of Philadelphia. In: Cancer. 2006 ; Vol. 107, No. 7. pp. 1597-1606.
@article{4184760e8abc48b5ac59e794832083c3,
title = "Gliomatosis cerebri: 20 Years of experience at the Children's Hospital of Philadelphia",
abstract = "BACKGROUND. Gliomatosis cerebri (GC) is a rare and typically fatal glial neoplasm of the central nervous system. In this report, the authors describe the largest cohort of children to date with GC and explore relations between potential prognostic factors, treatment, and survival. METHODS. Imaging, pathologic, and outcome data were reviewed from 13 patients who were diagnosed with GC and were treated at the Children's Hospital of Philadelphia (CHOP) between 1982 and 2005. All patients had GC confirmed by biopsy. Twelve patients received cranial irradiation, and 8 of those patients received adjuvant chemotherapy. A single patient age 1 year received chemotherapy alone. A review of the literature identified 51 pediatric patients with GC. RESULTS. The progression-free survival rate in this study was 13{\%} (range, 1.5-43 months), and the overall survival (OS) rate was 64{\%} (range, 6.5-67 months) at 2 years. OS was significantly shorter for patients who presented in the first decade of life (P = .04). The time to progression was prolonged significantly for patients who had no evidence of tumor enhancement on imaging studies (P = .03). When survival data from patients reported in the literature were combined with the CHOP cohort, treatment prolonged OS significantly (P = .003). CONCLUSIONS. The outcome of pediatric patients with GC was extremely poor; however, the current results indicated that treatment may prolong OS. Age < 10 years and contrast enhancement on magnetic resonance imaging studies at diagnosis may be risk factors for shorter survival in pediatric patients with GC.",
author = "Gregory Armstrong and Phillips, {Peter C.} and Rorke-Adams, {Lucy B.} and Judkins, {Alexander R.} and Localio, {A. Russell} and Fisher, {Michael J.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/cncr.22210",
language = "English (US)",
volume = "107",
pages = "1597--1606",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Gliomatosis cerebri

T2 - 20 Years of experience at the Children's Hospital of Philadelphia

AU - Armstrong, Gregory

AU - Phillips, Peter C.

AU - Rorke-Adams, Lucy B.

AU - Judkins, Alexander R.

AU - Localio, A. Russell

AU - Fisher, Michael J.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - BACKGROUND. Gliomatosis cerebri (GC) is a rare and typically fatal glial neoplasm of the central nervous system. In this report, the authors describe the largest cohort of children to date with GC and explore relations between potential prognostic factors, treatment, and survival. METHODS. Imaging, pathologic, and outcome data were reviewed from 13 patients who were diagnosed with GC and were treated at the Children's Hospital of Philadelphia (CHOP) between 1982 and 2005. All patients had GC confirmed by biopsy. Twelve patients received cranial irradiation, and 8 of those patients received adjuvant chemotherapy. A single patient age 1 year received chemotherapy alone. A review of the literature identified 51 pediatric patients with GC. RESULTS. The progression-free survival rate in this study was 13% (range, 1.5-43 months), and the overall survival (OS) rate was 64% (range, 6.5-67 months) at 2 years. OS was significantly shorter for patients who presented in the first decade of life (P = .04). The time to progression was prolonged significantly for patients who had no evidence of tumor enhancement on imaging studies (P = .03). When survival data from patients reported in the literature were combined with the CHOP cohort, treatment prolonged OS significantly (P = .003). CONCLUSIONS. The outcome of pediatric patients with GC was extremely poor; however, the current results indicated that treatment may prolong OS. Age < 10 years and contrast enhancement on magnetic resonance imaging studies at diagnosis may be risk factors for shorter survival in pediatric patients with GC.

AB - BACKGROUND. Gliomatosis cerebri (GC) is a rare and typically fatal glial neoplasm of the central nervous system. In this report, the authors describe the largest cohort of children to date with GC and explore relations between potential prognostic factors, treatment, and survival. METHODS. Imaging, pathologic, and outcome data were reviewed from 13 patients who were diagnosed with GC and were treated at the Children's Hospital of Philadelphia (CHOP) between 1982 and 2005. All patients had GC confirmed by biopsy. Twelve patients received cranial irradiation, and 8 of those patients received adjuvant chemotherapy. A single patient age 1 year received chemotherapy alone. A review of the literature identified 51 pediatric patients with GC. RESULTS. The progression-free survival rate in this study was 13% (range, 1.5-43 months), and the overall survival (OS) rate was 64% (range, 6.5-67 months) at 2 years. OS was significantly shorter for patients who presented in the first decade of life (P = .04). The time to progression was prolonged significantly for patients who had no evidence of tumor enhancement on imaging studies (P = .03). When survival data from patients reported in the literature were combined with the CHOP cohort, treatment prolonged OS significantly (P = .003). CONCLUSIONS. The outcome of pediatric patients with GC was extremely poor; however, the current results indicated that treatment may prolong OS. Age < 10 years and contrast enhancement on magnetic resonance imaging studies at diagnosis may be risk factors for shorter survival in pediatric patients with GC.

UR - http://www.scopus.com/inward/record.url?scp=33749626289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749626289&partnerID=8YFLogxK

U2 - 10.1002/cncr.22210

DO - 10.1002/cncr.22210

M3 - Article

VL - 107

SP - 1597

EP - 1606

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -